Abstract:Introduction: Using the Plectin1-targeting self-assembled peptide nanoparticle (PTNP) encapsulated with BET inhibitor JQ1 and PARP inhibitor Olaparib (Ola) to target accurately and suppress non-BRCA mutant pancreatic ductal adenocarcinoma (PDAC) synergistically Method: The morphologies of self-assembled peptide nanoparticle and drug-loaded nanoparticle were assessed by transmission electron microscopy (TEM); the entrapment efficiency of nanoparticles was analyzed by high performance liquid chromatography (HPLC); the drug release profiles of drug-loaded nanoparticle in vitro was evaluated by dialysis method; the targeting ability of nanoparticles was measured by flow cytometry and laser confocal microscopy; the synergetic effect was measured by western blot and flow cytometry. The in vivo stability and tumor targeting capability of peptide nanoparticle were determined by in vivo imaging system. The in vivo therapeutic effect was verified by orthotopic PDAC model. Result: The Plectin1-targeting self-assembled peptide could rapidly self-assemble into spherical nanoparticles. The diameter of PTNP was about 20 nm, and it turned to 50 nm after drug loading. After incubation for 48 hours in 10% serum solution, the morphology of drug-loaded nanoparticles PTNP-JQ1-Ola showed no obviously change, indicating that its structure was relatively stable. The entrapment efficiencies of JQ1 and Ola were both about 70%. The results of flow cytometry and laser confocal microscopy manifested that PTNP targeted Plectin1-overexpressed PDAC cells effectively. The western blot analysis indicated that PTNP loading JQ1 combined with Ola synergistically induced DNA damage and this nano-drug system resulted in higher apoptosis rate. The result of in vivo imaging system showed that PTNP had stronger accumulation in tumor site indicating the positive targeting effect of the nanoparticles on plectin1-overexpressed tumor. The PTNP-JQ1-Ola system had stronger inhibition on PDAC growth in orthotopic model. Conclusion: The plectin1-targeting self-assembled peptide nanoparticle loading with JQ1 and Ola targets PDAC effectively and thus improving the synthetic lethality capacity on non-BRCA mutant PDAC.

Epidermal Growth Factor Receptor Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib to Treat Pancreatic Cancer with Breast Cancer 2 (BRCA2) Mutation

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Synergistic Antitumor Efficacy of Rmv-Hu191 and Olaparib in Pancreatic Cancer by Generating Oxidative DNA Damage and ROS-dependent Apoptosis

A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.

Breaking the Iron Homeostasis: A “trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition

Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer.

Trap and Kill Strategy for Non-Brca Mutant Pancreatic Cancer by Co-Delivery of Olaparib and JQ1 with Plectin-1 Targeting Peptide Nanoparticles

EGFR-targeted and gemcitabine-incorporated chemogene for combinatorial pancreatic cancer treatment

Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy.

Synthetic Lethality in non-BRCA Mutant PDAC with Codelivery JQ1 and Olaparib via a Plectin1 Targeting Peptide Nanoparticle

Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer

Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib

Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer

Enhanced cisplatin chemotherapy sensitivity by self-assembled nanoparticles with Olaparib

Gemcitabine and Pin1 siRNA co-delivery with fucoidan-coated nano-liposomes for therapy of pancreatic cancer

Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma

Sustained co-delivery of gemcitabine and cis-platinum via biodegradable thermo-sensitive hydrogel for synergistic combination therapy of pancreatic cancer

Targeted PHA Microsphere-Loaded Triple-Drug System with Sustained Drug Release for Synergistic Chemotherapy and Gene Therapy

A Nano-targeted Co-delivery System Based on Gene Regulation and Molecular Blocking Strategy for Synergistic Enhancement of Platinum Chemotherapy Sensitivity in Ovarian Cancer

TPX2 Serves As a Novel Target for Expanding the Utility of PARPi in Pancreatic Cancer Through Conferring Synthetic Lethality

Enzyme‐Responsive Branched Glycopolymer‐Based Nanoassembly for Co‐Delivery of Paclitaxel and Akt Inhibitor toward Synergistic Therapy of Gastric Cancer